Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
Discontinued
Reference number: GID-TA10570
The Department for Health and Social Care has asked NICE to conduct an appraisal of Atezolizumab with paclitaxel for untreated unresectable advanced triple-negative breast cancer.
Please note that following on from information received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during early January 2021 when we will write to you about how you can get involved.